IQVIA (NYSE:IQV – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Truist Financial in a report issued on Tuesday, Benzinga reports. They presently have a $260.00 target price on the medical research company’s stock. Truist Financial’s price target points to a potential upside of 35.95% from the stock’s previous close.
IQV has been the subject of several other research reports. Morgan Stanley upped their target price on shares of IQVIA from $220.00 to $240.00 and gave the company an “overweight” rating in a report on Wednesday, August 2nd. Barclays dropped their price objective on IQVIA from $250.00 to $245.00 and set an “overweight” rating on the stock in a report on Friday. Citigroup upped their target price on IQVIA from $200.00 to $225.00 and gave the company a “neutral” rating in a research report on Wednesday, August 2nd. Stifel Nicolaus lifted their price target on IQVIA from $255.00 to $281.00 and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Finally, StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Thursday, September 28th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $251.64.
Read Our Latest Stock Analysis on IQV
IQVIA Stock Down 1.4 %
NYSE IQV traded down $2.63 on Tuesday, hitting $191.25. 360,021 shares of the stock were exchanged, compared to its average volume of 1,030,849. IQVIA has a fifty-two week low of $165.75 and a fifty-two week high of $241.86. The company has a 50-day moving average price of $215.44 and a 200-day moving average price of $207.69. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 2.16. The company has a market cap of $35.02 billion, a PE ratio of 32.90, a PEG ratio of 1.76 and a beta of 1.39.
IQVIA (NYSE:IQV – Get Free Report) last issued its earnings results on Tuesday, August 1st. The medical research company reported $2.22 EPS for the quarter, topping analysts’ consensus estimates of $2.09 by $0.13. The firm had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.70 billion. IQVIA had a net margin of 7.47% and a return on equity of 30.14%. Sell-side analysts anticipate that IQVIA will post 9.24 EPS for the current fiscal year.
Insider Activity
In related news, insider Constantinos Panagos sold 27,317 shares of the stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of $208.67, for a total transaction of $5,700,238.39. Following the completion of the transaction, the insider now directly owns 14,250 shares of the company’s stock, valued at $2,973,547.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.50% of the company’s stock.
Institutional Investors Weigh In On IQVIA
A number of hedge funds and other institutional investors have recently bought and sold shares of IQV. ST Germain D J Co. Inc. acquired a new stake in shares of IQVIA in the second quarter valued at about $33,000. Alberta Investment Management Corp lifted its position in shares of IQVIA by 7.4% during the 2nd quarter. Alberta Investment Management Corp now owns 168,502 shares of the medical research company’s stock valued at $37,874,000 after acquiring an additional 11,600 shares during the period. Stonebridge Capital Advisors LLC grew its holdings in shares of IQVIA by 0.9% in the 2nd quarter. Stonebridge Capital Advisors LLC now owns 9,208 shares of the medical research company’s stock worth $2,070,000 after acquiring an additional 80 shares during the period. Comerica Bank purchased a new position in IQVIA in the 2nd quarter valued at approximately $12,870,000. Finally, Osaic Holdings Inc. raised its holdings in IQVIA by 5.7% during the second quarter. Osaic Holdings Inc. now owns 63,137 shares of the medical research company’s stock worth $14,183,000 after purchasing an additional 3,414 shares during the last quarter. Institutional investors and hedge funds own 86.82% of the company’s stock.
About IQVIA
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and IQVIA wasn’t on the list.
While IQVIA currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
MarketBeat’s analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Source: marketbeat.com
